These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 8593496)
1. Pharmaceuticals. Record spending on R&D. Hosp Health Netw; 1996 Mar; 70(6):12. PubMed ID: 8593496 [No Abstract] [Full Text] [Related]
2. New estimates of drug development costs. Frank RG J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149 [No Abstract] [Full Text] [Related]
3. Costing drug development. Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358 [No Abstract] [Full Text] [Related]
4. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. Cockburn IM; Henderson RM J Health Econ; 2001 Nov; 20(6):1033-57. PubMed ID: 11758047 [TBL] [Abstract][Full Text] [Related]
5. Opinion: development of new drugs is still a risky business. Franks B N J Med; 2002; 99(1-2):60, 59. PubMed ID: 15326736 [No Abstract] [Full Text] [Related]
6. Probing the link between gross profitability and R&D spending. Lichtenberg FR Health Aff (Millwood); 2001; 20(5):221-2. PubMed ID: 11558707 [No Abstract] [Full Text] [Related]
7. 'More money needed for drug research'. Packer J Mod Healthc; 1991 Jun; 21(25):20. PubMed ID: 10111008 [No Abstract] [Full Text] [Related]
8. Drug costs: research and development costs: the great illusion. Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226 [TBL] [Abstract][Full Text] [Related]
9. The link between gross profitability and pharmaceutical R&D spending. Scherer FM Health Aff (Millwood); 2001; 20(5):216-20. PubMed ID: 11558706 [No Abstract] [Full Text] [Related]
10. Research spending surges. Souhrada L Hospitals; 1988 Dec; 62(24):48, 52, 56. PubMed ID: 3198077 [No Abstract] [Full Text] [Related]
11. $50 M for drug comparisons could produce valuable results. Carroll J Manag Care; 2004 Apr; 13(4):9-10. PubMed ID: 15146713 [No Abstract] [Full Text] [Related]
12. Can complexity be commercialized? Mack GS Nat Biotechnol; 2004 Oct; 22(10):1223-9. PubMed ID: 15470456 [No Abstract] [Full Text] [Related]
13. The price of innovation: new estimates of drug development costs. DiMasi JA; Hansen RW; Grabowski HG J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142 [TBL] [Abstract][Full Text] [Related]
14. Uneasy alliance--clinical investigators and the pharmaceutical industry. Bodenheimer T N Engl J Med; 2000 May; 342(20):1539-44. PubMed ID: 10816196 [No Abstract] [Full Text] [Related]
16. Drugs & money. In the high-stakes hunt for blockbuster pharmaceuticals, companies are pouring billions each year into R & D--with no guarantee that their products will ultimately pass FDA scrutiny. Novarro L Hosp Health Netw; 1997 Aug; 71(15):54-6. PubMed ID: 9274508 [No Abstract] [Full Text] [Related]
17. Merck's recall of rofecoxib--a strategic perspective. Oberholzer-Gee F; Inamdar SN N Engl J Med; 2004 Nov; 351(21):2147-9. PubMed ID: 15548771 [No Abstract] [Full Text] [Related]
18. Innovative drug R&D in China. Qi J; Wang Q; Yu Z; Chen X; Wang F Nat Rev Drug Discov; 2011 May; 10(5):333-4. PubMed ID: 21532556 [No Abstract] [Full Text] [Related]
19. Health care R&D spending doubles overall U.S. industry averages. Hosp Health Netw; 1994 Apr; 68(7):26. PubMed ID: 8136849 [No Abstract] [Full Text] [Related]
20. R&D deals boom in 2004. Lawrence S Nat Biotechnol; 2005 Sep; 23(9):1036. PubMed ID: 16151383 [No Abstract] [Full Text] [Related] [Next] [New Search]